← Leaderboards
Sonia M Thomas
Research Triangle Institute
$752,338,735
Attributed
$1,204,099,953
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $417.6M · FY2020–24$500M$375M$250M$125M$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,204,099,953 · 2
By mechanism
OT2$1,202,486,090 · 1
U24$1,613,863 · 1
Top collaborators
- Tracy L Nolen5 shared
Most similar at Research Triangle Institute
Same institution · by research overlap
- Tracy L Nolen$475,287,152
- Lisa Newman$22,725,934
- Craig Reist$22,725,934
Others in their field
Other Emerging Leaders on “Site”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Beth Baseler · Leidos Biomedical Research, Inc.$118,180,593
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Peter K Fritschel · California Institute Of Technology$78,820,000
Research focus
SiteUnited States National Institutes Of HealthIndustryReportingPrincipal InvestigatorNational Heart, Lung, And Blood InstituteClinical TrialsDesignFundingCommunicationInternationalLungData CollectionMedicalCardiovascular SystemClinicData Coordinating CenterData QualityEnsureClinical Trials DesignCollaborationsBiometryInfrastructureLead
Grant awards (17)
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$289,604,000
OT2 · FY2024 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$417,201,451
OT2 · FY2023 · HL · contact PI
2/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) Bleeding Data Coordinating Center$398,234
U24 · FY2023 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$171,499,647
OT2 · FY2022 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$18,821,635
OT2 · FY2022 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$6,395,703
OT2 · FY2022 · HL · contact PI
2/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) Bleeding Data Coordinating Center$395,332
U24 · FY2022 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$37,709,210
OT2 · FY2021 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$11,150,020
OT2 · FY2021 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$9,156,816
OT2 · FY2021 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$3,254,417
OT2 · FY2021 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$1,000,000
OT2 · FY2021 · HL · contact PI
2/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) Bleeding Data Coordinating Center$394,666
U24 · FY2021 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$169,000,000
OT2 · FY2020 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$50,000,000
OT2 · FY2020 · HL · contact PI
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center$17,693,191
OT2 · FY2020 · HL · contact PI
2/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) Bleeding Data Coordinating Center$425,631
U24 · FY2020 · HL · contact PI